Interventional Oncology Market by Devices & Consumables (RF, microwave, cryoablation. embolization), Procedures (Thermal Ablation, Non-Thermal Ablation, TACE, TARE, TAE), Cancer (Liver, Lung), End User (Hospital, Specialty Clinic) - Global Forecast to 2029

icon1
USD 4.23 BN
MARKET SIZE, 2030
icon2
CAGR 9.0%
(2025-2030)
icon3
534
REPORT PAGES
icon4
571
MARKET TABLES

OVERVIEW

Interventional Oncology Market Overview

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

The interventional oncology market is projected to reach USD 4.23 billion by 2029 from USD 2.75 billion in 2024, at a CAGR of 9.0% during the forecast period. The interventional oncology market is experiencing strong growth due to the rising global cancer burden and the increasing preference for minimally invasive treatment options.

KEY TAKEAWAYS

  • BY PRODUCT
    The product segment of the interventional oncology market is broadly categorized into ablation devices, embolization devices, and support devices. Among these, embolization devices, including microspheres and embolic agents, hold a significant share due to their wide use in procedures like transarterial chemoembolization (TACE) and radioembolization. Ablation devices such as radiofrequency, microwave, and cryoablation systems are also witnessing rapid growth, driven by their effectiveness in minimally invasive tumor destruction. Support devices, including catheters, guidewires, and microcatheters, play a crucial role in ensuring precision and safety during procedures, further complementing the overall market growth.
  • BY CANCER TYPE
    In the interventional oncology market, the cancer type segment is dominated by liver cancer due to the high prevalence of hepatocellular carcinoma and the strong effectiveness of procedures like transarterial chemoembolization (TACE) and radiofrequency ablation in its treatment. Lung and kidney cancers also represent significant shares, driven by the growing use of minimally invasive ablation therapies. Bone metastases form another key segment, as interventional techniques help in effective pain management and improving patient quality of life. The increasing incidence of these cancers and expanding clinical applications of interventional procedures are expected to further strengthen this segment’s growth.
  • BY PROCEDURE
    The procedure segment of the interventional oncology market is primarily driven by ablation, embolization, and supportive procedures, each playing a vital role in cancer management. Ablation techniques, including radiofrequency and microwave ablation, are widely used for localized tumors, while embolization methods such as transarterial chemoembolization (TACE) and radioembolization are gaining momentum for liver and other organ cancers.
  • BY END USER
    In the interventional oncology market, hospitals hold the largest share of the end-user segment, driven by the availability of advanced imaging technologies, specialized oncology departments, and skilled professionals to perform complex minimally invasive procedures.
  • BY REGION
    Asia Pacific is expected to grow fastest with a CAGR of 10.8%, due to the rising incidence of cancer, improving healthcare infrastructure, and increasing adoption of minimally invasive procedures across the region. Rapid economic growth, expanding access to advanced imaging technologies, and supportive government initiatives to strengthen cancer care are also driving demand.
  • COMPETITIVE LANDSCAPE
    The major market players have adopted both organic and inorganic strategies including partnerships and collaborations. For instance, Siemens Healthineers and Assistance Publique - Hôpitaux de Paris (AP-HP) (Paris) have signed a partnership to innovate healthcare. This agreement strengthens their collaboration in medical imaging, diagnostics, and advanced therapies to improve patient care and adapt to changes in the French healthcare system, aiming to co-develop new solutions for major health challenges like chronic diseases, cancer, and neurodegenerative conditions

The growth of the interventional oncology market is driven by several key factors, including the rising global burden of cancer, increasing demand for minimally invasive treatment options, and continuous technological advancements. Advances in the incidence of cancers of the liver, lungs, kidneys, and colon have been developing with many of these holding poor resectability, thereby indicating the increasing number of procedures in interventional oncology like transarterial chemoembolization (TACE), transcatheter arterial radioembolization (TARE), or percutaneous ablation. These methods provide targeted destruction of tumors with less systemic toxicity, faster recovery times, and fewer complications than do conventional surgical and chemotherapeutic modalities. In addition to this, greater preference for out-patient or day-care procedure due to higher cost-effectiveness and convenience will further add in the acceptance.

TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS

The major trends and disruptive forces within the interventional oncology market by contrasting traditional revenue sources such as legacy surgical procedures and conventional ablation devices with new sources including advanced image-guided therapies, minimally invasive treatments, and personalized therapy protocols. It traces how these innovations lead to high-growth opportunities through integration with digital health, AI-driven diagnostics, and precision medicine, ultimately impacting a spectrum of end users such as specialty oncology centers, telemedicine platforms, pharmacies, and insurance companies focused on value-based care delivery. This pathway highlights a shift from older device-centric business models toward holistic patient management, remote monitoring, and data-driven intervention for improved cancer outcomes.

Interventional Oncology Market Disruptions

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

MARKET DYNAMICS

Drivers
Impact
Level
  • Rising patient preference for minimally invasive procedure
  • Expansion of cancer patient population
RESTRAINTS
Impact
Level
  • High cost of interventional oncology
  • Unfavorable regulations
OPPORTUNITIES
Impact
Level
  • Emerging economies offer high growth potential
CHALLENGES
Impact
Level
  • Dearth of well-trained and skilled radiologist and oncologist
  • Strong market positioning of alternative therapies

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

Driver:Expansion of cancer patient population

Expansion in the patient population for cancer is an important growth driver in the interventional oncology market. In fact, due to multiple causes, including age, lifestyle factors, and increasing exposure to risk factors from environmental sources, the global incidence of cancer has increased steadily over time. The most common forms of cancers are those affecting the liver, lung, kidney, and colorectal regions; most of the cases are diagnosed at advance stages wherein conventional surgical interventions are either ineffective or cannot be applied. This increasing patient population is demanding more of minimally invasive, image-guided interventions by interventional oncologists, in providing potential palliative and curative options. Interventional oncology techniques include transarterial chemoembolization (TACE), transcatheter arterial radioembolization (TARE), and percutaneous ablation. These are of significant importance in the treatment of today's cancer, especially for patients with inoperable and metastatic tumors.

Restraint: High cost of interventional oncology

The expensive equipment involved with such procedures as well as sophisticated tools form some of the essential limitations holding the growth of interventional oncology. In particular, some treatments involving the disease under this treatment procedure are more sophisticated; thus, for TACE, TARE, and percutaneous ablation, for example, involve Yttrium-90 and a wide array of specialized catheters and embolic agents coupled with imaging technology in top shape, adding greatly to its expensive costs due to production and upscaling and other means.In addition, the highly specialized interventional radiologists and auxiliary staff increase the costs of the procedure. Most medical facilities, particularly in developing regions, are understaffed due to budgeting issues and inability to raise finance for the setup required, resulting in limited accessibility to interventional oncology.

Opportunity:Emerging economies offer high growth potential

Emerging economies, therefore, are significant growth opportunities for the interventional oncology market due to rapidly developing infrastructures of healthcare, an upsurge in cancer prevalence, and an increased demand for complex medical treatments in countries like those in Asia-Pacific, Latin America, and the Middle East & Africa. The regions experience high investment in modernising their healthcare facilities and improving accessibility to up-to-date medical equipment and delicate technologies. With an increasingly aging population, changing lifestyles, and rising rates of obesity, smoking, and hepatitis infection, the burden of cancer in these regions has made increasing access to more effective and accessible cancer treatment a pressing need. Interventional oncology is positioned well to meet these health care challenges because it lacks the invasiveness of traditional surgical oncology, recovery time is reduced, and it costs less. markets.

Challenge:Dearth of well-trained and skilled radiologist and oncologist

The interventional oncology market is currently under pressure by the inadequacy of well-trained and skilled interventional radiologists and oncologists, which would limit the widespread use of advanced minimally invasive cancer treatments. Tumor ablation, TACE, and TARE are interventional oncology procedures that require extremely specialized expertise in image-guided techniques, catheter navigation, and precision targeting of tumors. High procedure complexity demands serious training, access to advanced image equipment, and profound knowledge in the biology of the tumor before it is realized optimally during treatment. Conversely, however, access to adequate populations remains lacking across developing and emergent markets and areas where accessing medical education still poses a hurdle. Even inside the best-health-care systems the increasing demand exceeds even the supply to deliver interventional oncology practice.

MARKET ECOSYSTEM

The ecosystem market map of the interventional oncology market consists of a well-connected network of stakeholders that drive innovation, adoption, and growth. At the core are medical device manufacturers developing embolization agents, ablation systems, radioembolization therapies, and advanced delivery systems. Surrounding them are imaging system providers offering CT, MRI, and angiography solutions that guide interventional procedures with precision. Distributors and channel partners ensure availability of these devices across hospitals, ambulatory surgical centers, and specialty clinics, while group purchasing organizations (GPOs) influence procurement strategies. Supporting players include contract manufacturers and R&D partners driving technological advancements, along with regulatory agencies ensuring safety and compliance. Finally, end users such as interventional radiologists, oncologists, and healthcare providers form the demand center, supported by patients and advocacy groups who push for minimally invasive and cost-effective cancer treatments. This interconnected ecosystem fosters continuous innovation, efficient distribution, and wider accessibility of interventional oncology solutions worldwide.

Interventional Oncology Market Ecosystem

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

MARKET SEGMENTS

Interventional Oncology Market Segments

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

Interventional Oncology Market, By Product

Embolization devices are trends in the interventional oncology market since they are what is mainly behind the minimally invasive treatments offered for cancers, providing various benefits to conventional surgical interventions. The working principle of these devices is to cut off any blood supply to the tumors, thereby starving them of their oxygen and nutrients necessary for its growth. Because they have proven efficacy in the management of nonresectable cancers, particularly for liver cancer, embolization techniques, like TACE and radioembolization or SIRT, are gaining much more popularity. Advancements in embolic technologies also include the use of drug-eluting beads and radioactive microspheres to make the treatments more targeted and efficient. With an ever-increasing cancer burden around the world, growing awareness regarding minimally invasive therapies, and an increased trend towards outpatient care, the demand for embolization devices has surged rapidly.

Interventional Oncology Market, By Cancer Type

Liver cancer remains the biggest share of the market in interventional oncology due to the increase in prevalence, mortality, and the requirement for efficient and minimally invasive treatments. The most common form of liver cancer, hepatocellular carcinoma, has strong associations with risk factors like chronic hepatitis B and C, excessive alcohol consumption, and a growing incidence of non-alcoholic fatty liver disease. Interventional oncology embraces targeted approaches like transarterial chemoembolization, transarterial radioembolization, and percutaneous ablation that have been established to be beneficial in the treatment of unresectable liver cancer. These therapies are highly effective and provide a localized control of tumor with reduced systemic side effects when compared to the conventional chemotherapy that improves survival outcomes as compared to traditional chemotherapy.

Interventional Oncology Market, By Procedure

The largest share in the interventional oncology market is captured by transcatheter arterial radioembolization, also referred to as selective internal radiation therapy, due to its established success in the treatment of both primary and secondary liver cancers, which contribute to a considerable proportion of deaths related to cancer. This is the method where radioactive isotope-loaded microspheres, commonly Yttrium-90, are placed directly into the hepatic artery feeding the tumor. Localized radiation treatment gives an opportunity for the selective destruction of the tumor with the least exposure of systemic radiation to other healthy tissues. TARE gains acceptance due to its safe profile and better tolerance by the patients, as well as a reduced side effect profile compared to conventional chemotherapy and external radiation therapy. This is very useful for patients suffering with unresectable HCC and liver metastases of colorectal carcinoma where the treatment options are limited or less effective.

Interventional Oncology Market, By End User

Hospitals hold the largest share in the interventional oncology market because of robust infrastructure, cutting-edge technology, and multidisciplinary expertise that are necessary to perform complex interventional procedures. Specialized and minimally invasive techniques such as transarterial chemoembolization (TACE), transcatheter arterial radioembolization (TARE), and tumor ablation require advanced imaging systems, catheterization labs, and skilled interventional radiologists. Ideally, these capabilities are best served by tertiary care hospitals and specialized cancer centers. Hospitals also provide comprehensive, end-to-end care encompassing diagnosis, treatment, post-procedure management, and long-term follow-up, which makes them very attractive to patients who seek integrated and holistic cancer care solutions.

REGION

Asia Pacific to be fastest-growing region in global interventional oncology market during forecast period

Asia Pacific is projected to be the fastest growing region in the global interventional oncology market, driven by the rising prevalence of cancer and the growing demand for minimally invasive treatment options. Rapid improvements in healthcare infrastructure, coupled with increasing government investments in cancer care, are enabling wider adoption of advanced interventional procedures. The region is also benefiting from the availability of cost-effective treatment options, the expansion of medical tourism in countries like India, Thailand, and Singapore, and greater awareness among patients and clinicians about early cancer intervention. Additionally, the large patient pool, rising disposable incomes, and the entry of global manufacturers through partnerships with local distributors are further accelerating market growth in Asia Pacific.

Interventional Oncology Market Region

Interventional Oncology Market: COMPANY EVALUATION MATRIX

In the laparoscopic instruments market matrix, In the laparoscopic instruments market, Boston Scientific Corporation (Star) leads with scale, extensive distribution, and a broad solutions portfolio. Teleflex Incorporated (Emerging Leader) is gaining momentum by providing medical technology products that enhance clinical benefits, improve patient safety, and reduce total procedural costs. While Boston Scientific Corporation dominates through reach, Teleflex Incorporated innovation positions it for rapid growth toward the leaders’ quadrant.

Interventional Oncology Market Evaluation Metrics

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

KEY MARKET PLAYERS

MARKET SCOPE

REPORT METRIC DETAILS
Market Size Value in 2023 USD 2.53 Billion
Revenue Forecast in 2029 USD 4.23 Billion
Growth Rate CAGR of 9.0% from 2024-2029
Actual data 2019-2029
Base year 2023
Forecast period 2024-2029
Units considered Value (USD Million), Volume (Million Units)
Report Coverage Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, and Trends
Segments Covered
  • By Product:
    • Embolization Devices
    • Ablation Devices
    • Support Devices
  • By Cancer Type:
    • Liver
    • Kidney
    • Breast
    • Bone
    • Lung
    • Prostate
    • Other Cancer
  • By Procedure:
    • Transcatheter Arterial Radioembolization (TARE) or Selective Internal Radiatoion Therapy (SIRT)
    • Transcatheter Arterial Chemoembolization (TACE)
    • Transcatheter Arterial Embolization (TAE) or Bland Embolization
    • Thermal Tumour Ablation
    • Non-Thermal Tumour Ablation
  • By End User:
    • Hospitals
    • Speciality Clinics
    • Research & Academic Institutes
  • By Region
Regional Scope North America, Asia Pacific, Europe, Latin America, and the Middle East & Africa

WHAT IS IN IT FOR YOU: Interventional Oncology Market REPORT CONTENT GUIDE

Interventional Oncology Market Content Guide

DELIVERED CUSTOMIZATIONS

We have successfully delivered the following deep-dive customizations:

CLIENT REQUEST CUSTOMIZATION DELIVERED VALUE ADDS
Product Analysis Comparison of top interventional oncology devices: Embolization Devices, Ablation Devices, Support Devices Identify interconnections and supply chain blind spots; Detect customer migration trends across industries.
Company Information Key players: Siemens Healthineers AG (Varian) (US), Medtronic (Ireland), Boston Scientific Corporation (US), Terumo Corporation (Japan). Top 3-5 players market share analysis at APAC and European country level. Insights on revenue shifts towards emerging therapeutic applications and device innovations.
Geographic Analysis Detailed analysis on Rest of APAC was provided to one of the top players. Client focused on ASEAN Market country level analysis for device market. Country level demand mapping for new product launches and localization strategy planning

RECENT DEVELOPMENTS

  • December 2024 : AngioDynamics, Inc, expanding cancer treatment options and improving patient quality of life, announced receiving U.S. Food and Drug Administration (FDA) 510(k) clearance for the NanoKnife System for prostate tissue ablation.
  • December 2024 : Siemens Healthineers and AP-HP signed a partnership to innovate healthcare. This agreement strengthens their collaboration in medical imaging, diagnostics, and advanced therapies to improve patient care and adapt to changes in the French healthcare system, aiming to co-develop new.
  • November 2024 : Boston announced entering into a definitive agreement to acquire Intera Oncology Inc., a privately held medical device company that provides the Intera 3000 Hepatic Artery Infusion Pump and floxuridine, a chemotherapy drug, both of which are approved by the U.S. Food and Drug Administration.
  • September 2024 : Varian, a Siemens Healthineers company, announced a 10-year agreement with Ballad Health, to bring advanced oncology treatment services to serve patients in rural communities across the Appalachian Highlands in Northeast Tennessee, Southwest Virginia, northwestern North Carolina, and southeastern Kentucky.
  • November 2023 : ProSense received regulatory approval in India from the Central Drugs Standard Control Organisation (CDSCO) based on updated regulatory requirements.

 

Table of Contents

Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE
PAGE NO
1
INTRODUCTION
 
 
 
38
2
RESEARCH METHODOLOGY
 
 
 
44
3
EXECUTIVE SUMMARY
 
 
 
60
4
PREMIUM INSIGHTS
 
 
 
65
5
MARKET OVERVIEW
Interventional oncology market thrives on minimally invasive tech and funding amid regulatory and skill challenges.
 
 
 
69
 
5.1
INTRODUCTION
 
 
 
 
5.2
MARKET DYNAMICS
 
 
 
 
 
5.2.1
DRIVERS
 
 
 
 
 
5.2.1.1
RISING PREFERENCE FOR MINIMALLY INVASIVE PROCEDURES
 
 
 
 
5.2.1.2
GROWING PREVALENCE OF CANCER
 
 
 
 
5.2.1.3
INCREASING PUBLIC-PRIVATE FUNDING AND GOVERNMENT SUPPORT FOR INTERVENTIONAL ONCOLOGY
 
 
 
 
5.2.1.4
TECHNOLOGICAL ADVANCEMENTS IN INTERVENTIONAL ONCOLOGY
 
 
 
5.2.2
RESTRAINTS
 
 
 
 
 
5.2.2.1
HIGH COST OF INTERVENTIONAL ONCOLOGY
 
 
 
 
5.2.2.2
UNFAVORABLE REGULATIONS
 
 
 
5.2.3
OPPORTUNITIES
 
 
 
 
 
5.2.3.1
EMERGING ECONOMIES OFFER HIGH-GROWTH POTENTIAL
 
 
 
5.2.4
CHALLENGES
 
 
 
 
 
5.2.4.1
DEARTH OF WELL-TRAINED AND SKILLED RADIOLOGISTS AND ONCOLOGISTS
 
 
 
 
5.2.4.2
STRONG MARKET POSITION OF ALTERNATIVE THERAPIES
 
 
5.3
INDUSTRY TRENDS
 
 
 
 
 
5.3.1
INNOVATIONS IN IMAGING AND TREATMENT TECHNOLOGIES
 
 
 
 
5.3.2
INCREASING ADOPTION OF MINIMALLY INVASIVE PROCEDURES
 
 
 
5.4
VALUE CHAIN ANALYSIS
 
 
 
 
 
5.5
TECHNOLOGY ANALYSIS
 
 
 
 
 
5.5.1
KEY TECHNOLOGIES
 
 
 
 
 
5.5.1.1
ABLATION TECHNOLOGIES
 
 
 
 
5.5.1.2
EMBOLIZATION TECHNOLOGIES
 
 
 
5.5.2
COMPLEMENTARY TECHNOLOGY
 
 
 
 
 
5.5.2.1
LAPAROSCOPY
 
 
 
 
5.5.2.2
DIAGNOSTIC IMAGING
 
 
 
5.5.3
ADJACENT TECHNOLOGY
 
 
 
 
 
5.5.3.1
RADIATION THERAPY SYSTEMS
 
 
 
 
5.5.3.2
CHEMOTHERAPY
 
 
5.6
PORTER’S FIVE FORCES ANALYSIS
 
 
 
 
 
5.6.1
THREAT OF NEW ENTRANTS
 
 
 
 
5.6.2
THREAT OF SUBSTITUTES
 
 
 
 
5.6.3
BARGAINING POWER OF SUPPLIERS
 
 
 
 
5.6.4
BARGAINING POWER OF BUYERS
 
 
 
 
5.6.5
INTENSITY OF COMPETITIVE RIVALRY
 
 
 
5.7
KEY STAKEHOLDERS AND BUYING CRITERIA
 
 
 
 
 
 
5.7.1
KEY STAKEHOLDERS IN BUYING PROCESS
 
 
 
 
5.7.2
BUYING CRITERIA
 
 
 
5.8
REGULATORY LANDSCAPE
 
 
 
 
 
5.8.1
KEY REGULATORY BODIES AND GOVERNMENT AGENCIES
 
 
 
 
5.8.2
KEY REGULATORY GUIDELINES
 
 
 
 
 
5.8.2.1
US
 
 
 
 
5.8.2.2
CANADA
 
 
 
 
5.8.2.3
EUROPE
 
 
 
 
5.8.2.4
ASIA PACIFIC
 
 
 
 
5.8.2.5
BRAZIL
 
 
5.9
TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
 
 
 
 
5.10
PATENT ANALYSIS
 
 
 
 
 
 
5.10.1
PATENT PUBLICATION TRENDS FOR INTERVENTIONAL ONCOLOGY, JANUARY 2014–DECEMBER 2024
 
 
 
5.11
TRADE ANALYSIS
 
 
 
 
 
5.12
PRICING ANALYSIS
 
 
 
 
 
 
5.12.1
AVERAGE SELLING PRICE OF INTERVENTIONAL ONCOLOGY DEVICES, BY KEY PLAYER, 2023
 
 
 
 
5.12.2
AVERAGE SELLING PRICE OF INTERVENTIONAL ONCOLOGY DEVICES, BY KEY PLAYER, 2023 (USD)
 
 
 
 
5.12.3
AVERAGE SELLING PRICE TREND OF INTERVENTIONAL ONCOLOGY DEVICES, BY REGION, 2021–2023
 
 
 
5.13
KEY CONFERENCES AND EVENTS, 2025–2026
 
 
 
 
5.14
UNMET NEEDS AND END USER EXPECTATIONS
 
 
 
 
 
5.14.1
UNMET NEEDS
 
 
 
5.15
END USER EXPECTATIONS IN INTERVENTIONAL ONCOLOGY MARKET
 
 
 
 
5.16
ECOSYSTEM
 
 
 
 
 
5.17
CASE STUDIES
 
 
 
 
5.18
SUPPLY CHAIN ANALYSIS
 
 
 
 
 
5.19
ADJACENT MARKET ANALYSIS
 
 
 
 
5.20
INTERVENTIONAL ONCOLOGY MARKET, INVESTMENT AND FUNDING SCENARIO, 2020–2023
 
 
 
 
5.21
IMPACT OF GENERATIVE AI ON INTERVENTIONAL ONCOLOGY MARKET
 
 
 
6
INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES
Market Size & Growth Rate Forecast Analysis to 2029 in USD Million and Units | 46 Data Tables
 
 
 
107
 
6.1
INTRODUCTION
 
 
 
 
6.2
EMBOLIZATION DEVICES
 
 
 
 
 
6.2.1
RADIOEMBOLIC AGENTS
 
 
 
 
 
6.2.1.1
PRECISION-TARGETED THERAPY FOR CHALLENGING LIVER CANCERS TO BOOST MARKET
 
 
 
6.2.2
NON-RADIOACTIVE EMBOLIC AGENTS
 
 
 
 
 
6.2.2.1
NON-RADIATION EMITTING AGENTS TO PROPEL MARKET
 
 
 
 
6.2.2.2
MICROSPHERES
 
 
 
 
6.2.2.3
COATED BEADS
 
 
 
 
6.2.2.4
MICROPARTICLES
 
 
6.3
ABLATION DEVICES
 
 
 
 
 
6.3.1
RADIOFREQUENCY (RF) ABLATION DEVICES
 
 
 
 
 
6.3.1.1
EFFECTIVE TREATMENT OF SMALL OR DIFFICULT-TO-REACH TUMORS TO PROPEL MARKET GROWTH
 
 
 
6.3.2
MICROWAVE ABLATION DEVICES
 
 
 
 
 
6.3.2.1
SIMULTANEOUS TREATMENT OF MULTIPLE LESIONS TO DRIVE MARKET GROWTH
 
 
 
6.3.3
CRYOABLATION DEVICES
 
 
 
 
 
6.3.3.1
LEAST PAINFUL AND HIGHER PATIENT COMPATIBILITY TO DRIVE MARKET
 
 
 
6.3.4
OTHER ABLATION DEVICES
 
 
 
6.4
SUPPORT DEVICES
 
 
 
 
 
6.4.1
MICROCATHETERS
 
 
 
 
 
6.4.1.1
PRECISE DELIVERY OF THERAPEUTIC AGENTS TO TUMORS TO BOOST MARKET
 
 
 
6.4.2
GUIDEWIRES
 
 
 
 
 
6.4.2.1
ADVANCEMENTS IN GUIDEWIRE CONSTRUCTION AND LAUNCH OF NEW AND ADVANCED PRODUCTS TO PROPEL MARKET
 
 
 
6.4.3
OTHER SUPPORT DEVICES
 
 
7
INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE
Market Size & Growth Rate Forecast Analysis to 2029 in USD Million | 16 Data Tables
 
 
 
154
 
7.1
INTRODUCTION
 
 
 
 
7.2
LIVER CANCER
 
 
 
 
 
7.2.1
INCREASING DISEASE PREVALENCE AND RISING RESEARCH ACTIVITIES TO DRIVE MARKET GROWTH
 
 
 
7.3
KIDNEY CANCER
 
 
 
 
 
7.3.1
FIRST-LINE THERAPY PRESERVING MORE KIDNEY TISSUE THAN SURGERY TO BOOST MARKET
 
 
 
7.4
BREAST CANCER
 
 
 
 
 
7.4.1
HIGH PRECISION, BETTER COSMETIC OUTCOMES, COST-EFFECTIVENESS, AND GREATER PATIENT COMFORT TO PROPEL MARKET
 
 
 
7.5
LUNG CANCER
 
 
 
 
 
7.5.1
INCREASING NUMBER OF CANCER CASES TO DRIVE DEMAND
 
 
 
7.6
BONE CANCER
 
 
 
 
 
7.6.1
DIRECT ELIMINATION OF TUMORS AND PAIN RELIEF TO FUEL MARKET
 
 
 
7.7
PROSTATE CANCER
 
 
 
 
 
7.7.1
RISING INCIDENCE OF PROSTATE CANCER AND GROWING ADOPTION OF METAL-BASED FIDUCIAL MARKERS TO CONTRIBUTE TO MARKET GROWTH
 
 
 
7.8
OTHER CANCER TYPES
 
 
 
8
INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE
Market Size & Growth Rate Forecast Analysis to 2029 in USD Million | 12 Data Tables
 
 
 
177
 
8.1
INTRODUCTION
 
 
 
 
8.2
TRANSCATHETER ARTERIAL RADIOEMBOLIZATION/SELECTIVE INTERNAL RADIATION THERAPY (TARE/SIRT)
 
 
 
 
 
8.2.1
GREATER CLINICAL EFFICACY TO DRIVE MARKET GROWTH
 
 
 
8.3
TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION (TACE)
 
 
 
 
 
8.3.1
ABILITY TO TREAT SMALL AND LARGE-SIZED TUMORS TO DRIVE DEMAND
 
 
 
8.4
TRANSCATHETER ARTERIAL EMBOLIZATION/BLAND EMBOLIZATION (TAE)
 
 
 
 
 
8.4.1
INCREASING CLINICAL EVIDENCE IN FAVOR OF TARE AND TACE TO RESTRAIN MARKET GROWTH
 
 
 
8.5
THERMAL TUMOR ABLATION
 
 
 
 
 
8.5.1
GROWING CLINICAL EVIDENCE PROVING EFFICACY OF TREATMENT OF VARIOUS TYPES OF CANCERS TO DRIVE MARKET GROWTH
 
 
 
8.6
NON-THERMAL TUMOR ABLATION
 
 
 
 
 
8.6.1
POTENTIAL ALTERNATIVE TO THERMAL TUMOR ABLATION TO BOOST MARKET
 
 
9
INTERVENTIONAL ONCOLOGY MARKET, BY END USER
Market Size & Growth Rate Forecast Analysis to 2029 in USD Million | 8 Data Tables
 
 
 
194
 
9.1
INTRODUCTION
 
 
 
 
9.2
HOSPITALS
 
 
 
 
 
9.2.1
INCREASING NUMBER OF SURGERIES IN IN-PATIENT SETTINGS TO SUPPORT MARKET GROWTH
 
 
 
9.3
SPECIALTY CLINICS
 
 
 
 
 
9.3.1
INCREASING NUMBER OF CANCER CENTERS TO DRIVE MARKET GROWTH
 
 
 
9.4
RESEARCH & ACADEMIC INSTITUTES
 
 
 
 
 
9.4.1
COLLABORATIONS AMONG DEVICE MANUFACTURERS AND SUPPLIERS TO FUEL MARKET
 
 
10
INTERVENTIONAL ONCOLOGY MARKET, BY REGION
Comprehensive coverage of 8 Regions with country-level deep-dive of 14 Countries | 396 Data Tables.
 
 
 
205
 
10.1
INTRODUCTION
 
 
 
 
10.2
NORTH AMERICA
 
 
 
 
 
10.2.1
MACROECONOMIC OUTLOOK FOR NORTH AMERICA
 
 
 
 
10.2.2
US
 
 
 
 
 
10.2.2.1
RISING CANCER CASES AND PREFERENCE FOR ABLATION PROCEDURES TO BOOST MARKET
 
 
 
10.2.3
CANADA
 
 
 
 
 
10.2.3.1
SIGNIFICANT RISE IN CANCER CASES TO DRIVE MARKET GROWTH
 
 
10.3
EUROPE
 
 
 
 
 
10.3.1
MACROECONOMIC OUTLOOK FOR EUROPE
 
 
 
 
10.3.2
GERMANY
 
 
 
 
 
10.3.2.1
INCREASE IN INCIDENCE OF CANCER AND RISING GERIATRIC POPULATION TO FUEL MARKET
 
 
 
10.3.3
UK
 
 
 
 
 
10.3.3.1
INCREASING AWARENESS AND SUPPORT FOR CANCER-RELATED ACTIVITIES TO DRIVE MARKET
 
 
 
10.3.4
FRANCE
 
 
 
 
 
10.3.4.1
GROWING GERIATRIC POPULATION TO SUPPORT MARKET GROWTH
 
 
 
10.3.5
SPAIN
 
 
 
 
 
10.3.5.1
INCREASING GOVERNMENT FUNDING FOR RESEARCH TO SUPPORT MARKET GROWTH
 
 
 
10.3.6
ITALY
 
 
 
 
 
10.3.6.1
GROWING AWARENESS ABOUT CANCER AND TREATMENT OPTIONS TO SUPPORT MARKET GROWTH
 
 
 
10.3.7
REST OF EUROPE
 
 
 
10.4
ASIA PACIFIC
 
 
 
 
 
10.4.1
MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
 
 
 
 
10.4.2
JAPAN
 
 
 
 
 
10.4.2.1
RISING GERIATRIC POPULATION AND UNIVERSAL HEALTHCARE REIMBURSEMENT TO DRIVE MARKET
 
 
 
10.4.3
CHINA
 
 
 
 
 
10.4.3.1
INCREASING INCIDENCE OF CANCER TO DRIVE MARKET
 
 
 
10.4.4
INDIA
 
 
 
 
 
10.4.4.1
IMPROVING RESEARCH CAPABILITIES AND EXPANSION OF KEY PLAYERS TO DRIVE MARKET GROWTH
 
 
 
10.4.5
AUSTRALIA
 
 
 
 
 
10.4.5.1
RISING INVESTMENTS IN RESEARCH AND AWARENESS CAMPAIGNS TO SUPPORT MARKET GROWTH
 
 
 
10.4.6
SOUTH KOREA
 
 
 
 
 
10.4.6.1
RISING R&D AND PROMISING CLINICAL TRIALS TO POSITIVELY IMPACT MARKET GROWTH
 
 
 
10.4.7
REST OF ASIA PACIFIC
 
 
 
10.5
LATIN AMERICA
 
 
 
 
 
10.5.1
MACROECONOMIC OUTLOOK FOR LATIN AMERICA
 
 
 
 
10.5.2
BRAZIL
 
 
 
 
 
10.5.2.1
RISING INCIDENCE OF CANCER AND IMPROVING HEALTHCARE INFRASTRUCTURE TO FUEL MARKET
 
 
 
10.5.3
MEXICO
 
 
 
 
 
10.5.3.1
INCREASING AWARENESS CAMPAIGNS AND RISING INCIDENCE OF CANCER TO DRIVE MARKET GROWTH
 
 
 
10.5.4
REST OF LATIN AMERICA
 
 
 
10.6
MIDDLE EAST & AFRICA
 
 
 
 
 
10.6.1
MACROECONOMIC OUTLOOK
 
 
 
 
10.6.2
GCC COUNTRIES
 
 
 
 
 
10.6.2.1
BROADER HEALTHCARE MODERNIZATION INITIATIVES IN INTERVENTIONAL ONCOLOGY TO DRIVE MARKET
 
 
 
10.6.3
REST OF MIDDLE EAST & AFRICA
 
 
11
COMPETITIVE LANDSCAPE
Discover market dominance shifts and strategic moves shaping key players' competitive edge.
 
 
 
376
 
11.1
OVERVIEW
 
 
 
 
11.2
KEY PLAYER STRATEGIES/RIGHT TO WIN, 2021–2024
 
 
 
 
11.3
REVENUE ANALYSIS, 2019−2023
 
 
 
 
 
11.4
MARKET SHARE ANALYSIS, 2023
 
 
 
 
 
11.5
COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
 
 
 
 
 
 
11.5.1
STARS
 
 
 
 
11.5.2
EMERGING LEADERS
 
 
 
 
11.5.3
PERVASIVE PLAYERS
 
 
 
 
11.5.4
PARTICIPANTS
 
 
 
 
11.5.5
COMPANY FOOTPRINT: KEY PLAYERS, 2023
 
 
 
 
 
11.5.5.1
COMPANY FOOTPRINT
 
 
 
 
11.5.5.2
REGION FOOTPRINT
 
 
 
 
11.5.5.3
DEVICES & CONSUMABLES FOOTPRINT
 
 
 
 
11.5.5.4
CANCER TYPE FOOTPRINT
 
 
 
 
11.5.5.5
PROCEDURE FOOTPRINT
 
 
 
 
11.5.5.6
END USER FOOTPRINT
 
 
11.6
COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
 
 
 
 
 
 
11.6.1
PROGRESSIVE COMPANIES
 
 
 
 
11.6.2
DYNAMIC COMPANIES
 
 
 
 
11.6.3
STARTING BLOCKS
 
 
 
 
11.6.4
RESPONSIVE COMPANIES
 
 
 
 
11.6.5
COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES, 2023
 
 
 
 
 
11.6.5.1
DETAILED LIST OF KEY STARTUPS/SMES, 2023
 
 
 
 
11.6.5.2
COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
 
 
11.7
VALUATION & FINANCIAL METRICS
 
 
 
 
 
11.7.1
FINANCIAL METRICS
 
 
 
 
11.7.2
COMPANY VALUATION
 
 
 
11.8
BRAND COMPARISON
 
 
 
 
 
11.9
COMPETITIVE SCENARIO
 
 
 
 
 
11.9.1
PRODUCT & SERVICE LAUNCHES AND APPROVALS
 
 
 
 
11.9.2
DEALS
 
 
 
 
11.9.3
EXPANSIONS
 
 
12
COMPANY PROFILES
In-depth Company Profiles of Leading Market Players with detailed Business Overview, Product and Service Portfolio, Recent Developments, and Unique Analyst Perspective (MnM View)
 
 
 
399
 
12.1
KEY PLAYERS
 
 
 
 
 
12.1.1
SIEMENS HEALTHINEERS AG (VARIAN MEDICAL SYSTEMS, INC)
 
 
 
 
 
12.1.1.1
BUSINESS OVERVIEW
 
 
 
 
12.1.1.2
PRODUCTS/SOLUTIONS/SERVICES OFFERED
 
 
 
 
12.1.1.3
RECENT DEVELOPMENTS
 
 
 
 
12.1.1.4
MNM VIEW
 
 
 
12.1.2
BOSTON SCIENTIFIC CORPORATION
 
 
 
 
12.1.3
MEDTRONIC
 
 
 
 
12.1.4
TERUMO CORPORATION
 
 
 
 
12.1.5
MERIT MEDICAL SYSTEMS
 
 
 
 
12.1.6
JOHNSON & JOHNSON MEDTECH (ETHICON)
 
 
 
 
12.1.7
TELEFLEX INCORPORATED
 
 
 
 
12.1.8
ANGIODYNAMICS
 
 
 
 
12.1.9
STRYKER
 
 
 
 
12.1.10
IMBIOTECHNOLOGIES LTD.
 
 
 
 
12.1.11
COOK
 
 
 
 
12.1.12
ICECURE MEDICAL
 
 
 
 
12.1.13
MEDWAVES, INC.
 
 
 
 
12.1.14
PROFOUND MEDICAL
 
 
 
 
12.1.15
RF MEDICAL CO., LTD.
 
 
 
 
12.1.16
MINIMAX MEDICAL LIMITED
 
 
 
 
12.1.17
ABK BIOMEDICAL INC.
 
 
 
 
12.1.18
OLYMPUS CORPORATION
 
 
 
 
12.1.19
SURGNOVA
 
 
 
 
12.1.20
STARMED AMERICA
 
 
 
12.2
OTHER PLAYERS
 
 
 
 
 
12.2.1
SIRTEX SIR-SPHERES PTY LTD.
 
 
 
 
12.2.2
GUERBET
 
 
 
 
12.2.3
ACCURAY INCORPORATED
 
 
 
 
12.2.4
EMBOLX, INC.
 
 
 
 
12.2.5
SONABLATE CORP.
 
 
13
APPENDIX
 
 
 
448
 
13.1
DISCUSSION GUIDE
 
 
 
 
13.2
KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
 
 
 
 
13.3
CUSTOMIZATION OPTIONS
 
 
 
 
13.4
RELATED REPORTS
 
 
 
 
13.5
AUTHOR DETAILS
 
 
 
LIST OF TABLES
 
 
 
 
 
TABLE 1
STANDARD CURRENCY CONVERSION RATES
 
 
 
 
TABLE 2
RISK ASSESSMENT: INTERVENTIONAL ONCOLOGY MARKET
 
 
 
 
TABLE 3
INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF EMBOLIZATION DEVICES, ABLATION DEVICES, AND SUPPORT DEVICES
 
 
 
 
TABLE 4
KEY BUYING CRITERIA FOR EMBOLIZATION DEVICES, ABLATION DEVICES, AND SUPPORT DEVICES
 
 
 
 
TABLE 5
NORTH AMERICA: LIST OF REGULATORY BODIES AND GOVERNMENT AGENCIES
 
 
 
 
TABLE 6
EUROPE: LIST OF REGULATORY BODIES AND GOVERNMENT AGENCIES
 
 
 
 
TABLE 7
ASIA PACIFIC: LIST OF REGULATORY BODIES AND GOVERNMENT AGENCIES
 
 
 
 
TABLE 8
LATIN AMERICA: LIST OF REGULATORY BODIES AND GOVERNMENT AGENCIES
 
 
 
 
TABLE 9
MIDDLE EAST & AFRICA: LIST OF REGULATORY BODIES AND GOVERNMENT AGENCIES
 
 
 
 
TABLE 10
US FDA: MEDICAL DEVICE CLASSIFICATION
 
 
 
 
TABLE 11
US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
 
 
 
 
TABLE 12
CANADA: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
 
 
 
 
TABLE 13
JAPAN: PMDA CLASSIFICATION OF ABLATION DEVICES
 
 
 
 
TABLE 14
JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PHARMACEUTICAL AND MEDICAL DEVICE AGENCY (PMDA)
 
 
 
 
TABLE 15
CHINA: CLASSIFICATION OF MEDICAL DEVICES
 
 
 
 
TABLE 16
INDIA: CDSCO CLASSIFICATION OF ABLATION DEVICES
 
 
 
 
TABLE 17
LIST OF PATENTS IN INTERVENTIONAL ONCOLOGY MARKET, 2021–2024
 
 
 
 
TABLE 18
IMPORT DATA FOR INTERVENTIONAL ONCOLOGY (HS CODE 9018), BY COUNTRY, 2019–2023 (USD THOUSAND)
 
 
 
 
TABLE 19
EXPORT DATA FOR INTERVENTIONAL ONCOLOGY (HS CODE 9018), BY COUNTRY, 2019–2023 (USD THOUSAND)
 
 
 
 
TABLE 20
AVERAGE SELLING PRICE OF INTERVENTIONAL ONCOLOGY DEVICES, BY KEY PLAYER, 2023 (USD)
 
 
 
 
TABLE 21
AVERAGE SELLING PRICE TREND OF INTERVENTIONAL ONCOLOGY DEVICES, BY REGION, 2021–2023
 
 
 
 
TABLE 22
INTERVENTIONAL ONCOLOGY MARKET: KEY CONFERENCES & EVENTS, 2025–2026
 
 
 
 
TABLE 23
END USER EXPECTATIONS FOR EMBOLIZATION DEVICES, ABLATION DEVICES, AND SUPPORT DEVICES
 
 
 
 
TABLE 24
INTERVENTIONAL ONCOLOGY MARKET: ECOSYSTEM ANALYSIS
 
 
 
 
TABLE 25
TREATMENT OF HEPATOCELLULAR CARCINOMA WITH ARTERIOPORTAL SHUNTING USING BALLOON-ASSISTED TRANSARTERIAL YTTRIUM-90 RADIATION SEGMENTECTOMY
 
 
 
 
TABLE 26
RADIOFREQUENCY ABLATION ANALYSIS CASE STUDY
 
 
 
 
TABLE 27
UPPER POLE ANGIOMYOLIPOMA (AML) EMBOLIZATION
 
 
 
 
TABLE 28
INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 29
INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 30
INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 31
INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 32
INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY REGION, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 33
INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY REGION, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 34
RADIOEMBOLIC AGENTS OFFERED BY MAJOR MARKET PLAYERS
 
 
 
 
TABLE 35
INTERVENTIONAL ONCOLOGY MARKET FOR RADIOEMBOLIC AGENTS, BY REGION, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 36
INTERVENTIONAL ONCOLOGY MARKET FOR RADIOEMBOLIC AGENTS, BY REGION, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 37
NON-RADIOACTIVE EMBOLIC AGENTS OFFERED BY MAJOR MARKET PLAYERS
 
 
 
 
TABLE 38
INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE EMBOLIC AGENTS, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 39
INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE EMBOLIC AGENTS, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 40
INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE EMBOLIC AGENTS, BY REGION, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 41
INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE EMBOLIC AGENTS, BY REGION, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 42
INTERVENTIONAL ONCOLOGY MARKET FOR MICROSPHERES, BY REGION, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 43
INTERVENTIONAL ONCOLOGY MARKET FOR MICROSPHERES, BY REGION, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 44
INTERVENTIONAL ONCOLOGY MARKET FOR COATED BEADS, BY REGION, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 45
INTERVENTIONAL ONCOLOGY MARKET FOR COATED BEADS, BY REGION, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 46
MAJOR BRANDS OF MICROCARRIERS
 
 
 
 
TABLE 47
INTERVENTIONAL ONCOLOGY MARKET FOR MICROPARTICLES, BY REGION, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 48
INTERVENTIONAL ONCOLOGY MARKET FOR MICROPARTICLES, BY REGION, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 49
INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 50
INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 51
INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY REGION, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 52
INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY REGION, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 53
RADIOFREQUENCY ABLATION DEVICES OFFERED BY MAJOR MARKET PLAYERS
 
 
 
 
TABLE 54
INTERVENTIONAL ONCOLOGY MARKET FOR RADIOFREQUENCY ABLATION DEVICES, BY REGION, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 55
INTERVENTIONAL ONCOLOGY MARKET FOR RADIOFREQUENCY ABLATION DEVICES, BY REGION, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 56
RADIOFREQUENCY ABLATION SYSTEMS, BY REGION, 2023–2029 (THOUSAND UNITS)
 
 
 
 
TABLE 57
INTERVENTIONAL ONCOLOGY MARKET FOR MICROWAVE ABLATION DEVICES, BY REGION, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 58
INTERVENTIONAL ONCOLOGY MARKET FOR MICROWAVE ABLATION DEVICES, BY REGION, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 59
MICROWAVE ABLATION SYSTEMS, BY REGION, 2023–2029 (THOUSAND UNITS)
 
 
 
 
TABLE 60
INTERVENTIONAL ONCOLOGY MARKET FOR CRYOABLATION DEVICES, BY REGION, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 61
INTERVENTIONAL ONCOLOGY MARKET FOR CRYOABLATION DEVICES, BY REGION, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 62
INTERVENTIONAL ONCOLOGY MARKET FOR OTHER ABLATION DEVICES, BY REGION, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 63
INTERVENTIONAL ONCOLOGY MARKET FOR OTHER ABLATION DEVICES, BY REGION, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 64
INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 65
INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 66
INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY REGION, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 67
INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY REGION, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 68
INTERVENTIONAL ONCOLOGY MARKET FOR MICROCATHETERS, BY REGION, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 69
INTERVENTIONAL ONCOLOGY MARKET FOR MICROCATHETERS, BY REGION, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 70
INTERVENTIONAL ONCOLOGY MARKET FOR GUIDEWIRES, BY REGION, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 71
INTERVENTIONAL ONCOLOGY MARKET FOR GUIDEWIRES, BY REGION, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 72
INTERVENTIONAL ONCOLOGY MARKET FOR OTHER SUPPORT DEVICES, BY REGION, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 73
INTERVENTIONAL ONCOLOGY MARKET FOR OTHER SUPPORT DEVICES, BY REGION, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 74
INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 75
INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 76
INTERVENTIONAL ONCOLOGY MARKET FOR LIVER CANCER, BY REGION, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 77
INTERVENTIONAL ONCOLOGY MARKET FOR LIVER CANCER, BY REGION, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 78
INTERVENTIONAL ONCOLOGY MARKET FOR KIDNEY CANCER, BY REGION, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 79
INTERVENTIONAL ONCOLOGY MARKET FOR KIDNEY CANCER, BY REGION, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 80
INTERVENTIONAL ONCOLOGY MARKET FOR BREAST CANCER, BY REGION, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 81
INTERVENTIONAL ONCOLOGY MARKET FOR BREAST CANCER, BY REGION, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 82
INTERVENTIONAL ONCOLOGY MARKET FOR LUNG CANCER, BY REGION, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 83
INTERVENTIONAL ONCOLOGY MARKET FOR LUNG CANCER, BY REGION, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 84
INTERVENTIONAL ONCOLOGY MARKET FOR BONE CANCER, BY REGION, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 85
INTERVENTIONAL ONCOLOGY MARKET FOR BONE CANCER, BY REGION, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 86
INTERVENTIONAL ONCOLOGY MARKET FOR PROSTATE CANCER, BY REGION, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 87
INTERVENTIONAL ONCOLOGY MARKET FOR PROSTATE CANCER, BY REGION, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 88
INTERVENTIONAL ONCOLOGY MARKET FOR OTHER CANCER TYPES, BY REGION, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 89
INTERVENTIONAL ONCOLOGY MARKET FOR OTHER CANCER TYPES, BY REGION, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 90
INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 91
INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 92
INTERVENTIONAL ONCOLOGY MARKET FOR TRANSCATHETER ARTERIAL RADIOEMBOLIZATION/SELECTIVE INTERNAL RADIATION THERAPY (TARE/SIRT), BY REGION, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 93
INTERVENTIONAL ONCOLOGY MARKET FOR TRANSCATHETER ARTERIAL RADIOEMBOLIZATION/SELECTIVE INTERNAL RADIATION THERAPY (TARE/SIRT), BY REGION, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 94
INTERVENTIONAL ONCOLOGY MARKET FOR TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION (TACE), BY REGION, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 95
INTERVENTIONAL ONCOLOGY MARKET FOR TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION (TACE), BY REGION, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 96
INTERVENTIONAL ONCOLOGY MARKET FOR TRANSCATHETER ARTERIAL EMBOLIZATION/BLAND EMBOLIZATION (TAE), BY REGION, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 97
INTERVENTIONAL ONCOLOGY MARKET FOR TRANSCATHETER ARTERIAL EMBOLIZATION/BLAND EMBOLIZATION (TAE), BY REGION, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 98
INTERVENTIONAL ONCOLOGY MARKET FOR THERMAL TUMOR ABLATION, BY REGION, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 99
INTERVENTIONAL ONCOLOGY MARKET FOR THERMAL TUMOR ABLATION, BY REGION, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 100
INTERVENTIONAL ONCOLOGY MARKET FOR NON-THERMAL TUMOR ABLATION, BY REGION, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 101
INTERVENTIONAL ONCOLOGY MARKET FOR NON-THERMAL TUMOR ABLATION, BY REGION, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 102
INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 103
INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 104
INTERVENTIONAL ONCOLOGY MARKET FOR HOSPITALS, BY REGION, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 105
INTERVENTIONAL ONCOLOGY MARKET FOR HOSPITALS, BY REGION, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 106
INTERVENTIONAL ONCOLOGY MARKET FOR SPECIALTY CLINICS, BY REGION, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 107
INTERVENTIONAL ONCOLOGY MARKET FOR SPECIALTY CLINICS, BY REGION, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 108
INTERVENTIONAL ONCOLOGY MARKET FOR RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 109
INTERVENTIONAL ONCOLOGY MARKET FOR RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 110
INTERVENTIONAL ONCOLOGY MARKET, BY REGION, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 111
INTERVENTIONAL ONCOLOGY MARKET, BY REGION, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 112
NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY COUNTRY, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 113
NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY COUNTRY, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 114
NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 115
NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 116
NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 117
NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 118
NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 119
NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 120
NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 121
NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 122
NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 123
NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 124
NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 125
NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 126
NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 127
NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 128
NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 129
NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 130
US: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 131
US: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 132
US: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 133
US: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 134
US: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 135
US: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 136
US: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 137
US: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 138
US: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 139
US: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 140
US: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 141
US: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 142
US: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 143
US: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 144
US: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 145
US: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 146
CANADA: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 147
CANADA: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 148
CANADA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 149
CANADA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 150
CANADA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 151
CANADA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 152
CANADA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 153
CANADA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 154
CANADA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 155
CANADA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 156
CANADA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 157
CANADA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 158
CANADA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 159
CANADA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 160
CANADA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 161
CANADA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 162
EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY COUNTRY, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 163
EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY COUNTRY, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 164
EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 165
EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 166
EUROPE: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 167
EUROPE: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 168
EUROPE: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 169
EUROPE: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 170
EUROPE: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 171
EUROPE: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 172
EUROPE: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 173
EUROPE: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 174
EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 175
EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 176
EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 177
EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 178
EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 179
EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 180
GERMANY: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 181
GERMANY: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 182
GERMANY: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 183
GERMANY: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 184
GERMANY: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 185
GERMANY: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 186
GERMANY: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 187
GERMANY: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 188
GERMANY: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 189
GERMANY: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 190
GERMANY: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 191
GERMANY: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 192
GERMANY: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 193
GERMANY: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 194
GERMANY: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 195
GERMANY: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 196
UK: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 197
UK: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 198
UK: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 199
UK: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 200
UK: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 201
UK: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 202
UK: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 203
UK: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 204
UK: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 205
UK: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 206
UK: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 207
UK: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 208
UK: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 209
UK: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 210
UK: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 211
UK: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 212
FRANCE: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 213
FRANCE: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 214
FRANCE: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 215
FRANCE: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 216
FRANCE: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 217
FRANCE: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 218
FRANCE: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 219
FRANCE: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 220
FRANCE: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 221
FRANCE: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 222
FRANCE: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 223
FRANCE: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 224
FRANCE: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 225
FRANCE: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 226
FRANCE: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 227
FRANCE: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 228
SPAIN: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 229
SPAIN: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 230
SPAIN: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 231
SPAIN: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 232
SPAIN: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 233
SPAIN: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 234
SPAIN: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 235
SPAIN: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 236
SPAIN: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 237
SPAIN: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 238
SPAIN: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 239
SPAIN: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 240
SPAIN: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 241
SPAIN: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 242
SPAIN: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 243
SPAIN: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 244
ITALY: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 245
ITALY: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 246
ITALY: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 247
ITALY: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 248
ITALY: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 249
ITALY: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 250
ITALY: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 251
ITALY: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 252
ITALY: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 253
ITALY: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 254
ITALY: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 255
ITALY: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 256
ITALY: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 257
ITALY: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 258
ITALY: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 259
ITALY: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 260
REST OF EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 261
REST OF EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 262
REST OF EUROPE: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 263
REST OF EUROPE: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 264
REST OF EUROPE INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 265
REST OF EUROPE: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 266
REST OF EUROPE: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 267
REST OF EUROPE: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 268
REST OF EUROPE: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 269
REST OF EUROPE: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 270
REST OF EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 271
REST OF EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 272
REST OF EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 273
REST OF EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 274
REST OF EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 275
REST OF EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 276
ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY COUNTRY, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 277
ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY COUNTRY, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 278
ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 279
ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 280
ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 281
ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 282
ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 283
ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 284
ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 285
ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 286
ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 287
ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 288
ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 289
ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 290
ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 291
ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 292
ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 293
ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 294
JAPAN: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 295
JAPAN: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 296
JAPAN: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 297
JAPAN: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 298
JAPAN: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 299
JAPAN: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 300
JAPAN: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 301
JAPAN: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 302
JAPAN: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 303
JAPAN: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 304
JAPAN: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 305
JAPAN: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 306
JAPAN: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 307
JAPAN: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 308
JAPAN: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 309
JAPAN: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 310
CHINA: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 311
CHINA: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 312
CHINA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 313
CHINA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 314
CHINA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 315
CHINA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 316
CHINA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 317
CHINA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 318
CHINA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 319
CHINA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 320
CHINA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 321
CHINA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 322
CHINA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 323
CHINA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 324
CHINA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 325
CHINA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 326
INDIA: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 327
INDIA: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 328
INDIA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 329
INDIA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 330
INDIA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 331
INDIA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 332
INDIA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 333
INDIA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 334
INDIA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 335
INDIA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 336
INDIA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 337
INDIA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 338
INDIA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 339
INDIA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 340
INDIA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 341
INDIA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 342
AUSTRALIA: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 343
AUSTRALIA: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 344
AUSTRALIA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 345
AUSTRALIA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 346
AUSTRALIA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 347
AUSTRALIA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 348
AUSTRALIA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 349
AUSTRALIA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 350
AUSTRALIA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 351
AUSTRALIA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 352
AUSTRALIA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 353
AUSTRALIA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 354
AUSTRALIA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 355
AUSTRALIA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 356
AUSTRALIA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 357
AUSTRALIA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 358
SOUTH KOREA: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 359
SOUTH KOREA: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 360
SOUTH KOREA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 361
SOUTH KOREA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 362
SOUTH KOREA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 363
SOUTH KOREA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 364
SOUTH KOREA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 365
SOUTH KOREA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 366
SOUTH KOREA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 367
SOUTH KOREA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 368
SOUTH KOREA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 369
SOUTH KOREA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 370
SOUTH KOREA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 371
SOUTH KOREA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 372
SOUTH KOREA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 373
SOUTH KOREA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 374
REST OF ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 375
REST OF ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 376
REST OF ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 377
REST OF ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 378
REST OF ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 379
REST OF ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 380
REST OF ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 381
REST OF ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 382
REST OF ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 383
REST OF ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 384
REST OF ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 385
REST OF ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 386
REST OF ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 387
REST OF ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 388
REST OF ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 389
REST OF ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 390
LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY COUNTRY, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 391
LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY COUNTRY, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 392
LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 393
LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 394
LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 395
LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 396
LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 397
LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 398
LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 399
LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 400
LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 401
LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 402
LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 403
LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 404
LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 405
LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 406
LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 407
LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 408
BRAZIL: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 409
BRAZIL: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 410
BRAZIL: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 411
BRAZIL: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 412
BRAZIL: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 413
BRAZIL: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 414
BRAZIL: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 415
BRAZIL: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 416
BRAZIL: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 417
BRAZIL: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 418
BRAZIL: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 419
BRAZIL: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 420
BRAZIL: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 421
BRAZIL: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 422
BRAZIL: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 423
BRAZIL: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 424
MEXICO: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 425
MEXICO: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 426
MEXICO: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 427
MEXICO: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 428
MEXICO: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 429
MEXICO: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 430
MEXICO: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 431
MEXICO: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 432
MEXICO: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 433
MEXICO: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 434
MEXICO: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 435
MEXICO: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 436
MEXICO: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 437
MEXICO: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 438
MEXICO: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 439
MEXICO: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 440
REST OF LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 441
REST OF LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 442
REST OF LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 443
REST OF LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 444
REST OF LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 445
REST OF LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 446
REST OF LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 447
REST OF LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 448
REST OF LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 449
REST OF LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 450
REST OF LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 451
REST OF LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 452
REST OF LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 453
REST OF LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 454
REST OF LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 455
REST OF LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 456
MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET, BY COUNTRY, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 457
MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET, BY COUNTRY, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 458
MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 459
MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 460
MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 461
MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 462
MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 463
MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 464
MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 465
MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 466
MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 467
MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 468
MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 469
MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 470
MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 471
MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 472
MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 473
MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 474
GCC COUNTRIES: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 475
GCC COUNTRIES: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 476
GCC COUNTRIES: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 477
GCC COUNTRIES: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 478
GCC COUNTRIES: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 479
GCC COUNTRIES: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 480
GCC COUNTRIES: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 481
GCC COUNTRIES: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 482
GCC COUNTRIES: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 483
GCC COUNTRIES: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 484
GCC COUNTRIES: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 485
GCC COUNTRIES: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 486
GCC COUNTRIES: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 487
GCC COUNTRIES: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 488
GCC COUNTRIES: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 489
GCC COUNTRIES: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 490
REST OF MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 491
REST OF MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 492
REST OF MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 493
REST OF MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 494
REST OF MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 495
REST OF MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 496
REST OF MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 497
REST OF MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 498
REST OF MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 499
REST OF MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 500
REST OF MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 501
REST OF MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 502
REST OF MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 503
REST OF MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 504
REST OF MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019–2023 (USD MILLION)
 
 
 
 
TABLE 505
REST OF MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024–2029 (USD MILLION)
 
 
 
 
TABLE 506
STRATEGIES ADOPTED BY KEY PLAYERS IN INTERVENTIONAL ONCOLOGY MARKET, JANUARY 2021–DECEMBER 2024
 
 
 
 
TABLE 507
INTERVENTIONAL ONCOLOGY MARKET: DEGREE OF COMPETITION
 
 
 
 
TABLE 508
INTERVENTIONAL ONCOLOGY MARKET: REGION FOOTPRINT
 
 
 
 
TABLE 509
INTERVENTIONAL ONCOLOGY MARKET: DEVICES & CONSUMABLES FOOTPRINT
 
 
 
 
TABLE 510
INTERVENTIONAL ONCOLOGY MARKET: CANCER TYPE FOOTPRINT
 
 
 
 
TABLE 511
INTERVENTIONAL ONCOLOGY MARKET: PROCEDURE FOOTPRINT
 
 
 
 
TABLE 512
INTERVENTIONAL ONCOLOGY MARKET: END USER FOOTPRINT
 
 
 
 
TABLE 513
INTERVENTIONAL ONCOLOGY MARKET: DETAILED LIST OF KEY STARTUPS/ SMES, 2023
 
 
 
 
TABLE 514
INTERVENTIONAL ONCOLOGY MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
 
 
 
 
TABLE 515
INTERVENTIONAL ONCOLOGY MARKET: PRODUCT & SERVICE LAUNCHES AND APPROVALS, JANUARY 2021–DECEMBER 2024
 
 
 
 
TABLE 516
INTERVENTIONAL ONCOLOGY MARKET: DEALS, JANUARY 2021–DECEMBER 2024
 
 
 
 
TABLE 517
INTERVENTIONAL ONCOLOGY MARKET: EXPANSIONS, JANUARY 2021–DECEMBER 2024
 
 
 
 
TABLE 518
SIEMENS HEALTHINEERS AG (VARIAN): COMPANY OVERVIEW
 
 
 
 
TABLE 519
SIEMENS HEALTHINEERS AG (VARIAN): PRODUCTS/SOLUTIONS/ SERVICES OFFERED
 
 
 
 
TABLE 520
SIEMENS HEALTHINEERS AG (VARIAN): PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–DECEMBER 2024
 
 
 
 
TABLE 521
SIEMENS HEALTHINEERS AG (VARIAN): DEALS, JANUARY 2021–DECEMBER 2024
 
 
 
 
TABLE 522
BOSTON SCIENTIFIC CORPORATION: COMPANY OVERVIEW
 
 
 
 
TABLE 523
BOSTON SCIENTIFIC CORPORATION: PRODUCTS/SOLUTIONS/SERVICES OFFERED
 
 
 
 
TABLE 524
BOSTON SCIENTIFIC CORPORATION: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–DECEMBER 2024
 
 
 
 
TABLE 525
BOSTON SCIENTIFIC CORPORATION: DEALS, JANUARY 2021–DECEMBER 2024
 
 
 
 
TABLE 526
MEDTRONIC: COMPANY OVERVIEW
 
 
 
 
TABLE 527
MEDTRONIC: PRODUCTS/SOLUTIONS/SERVICES OFFERED
 
 
 
 
TABLE 528
TERUMO CORPORATION: COMPANY OVERVIEW
 
 
 
 
TABLE 529
TERUMO CORPORATION: PRODUCTS/SOLUTIONS/SERVICES OFFERED
 
 
 
 
TABLE 530
TERUMO CORPORATION: EXPANSIONS, JANUARY 2021– DECEMBER 2024
 
 
 
 
TABLE 531
MERIT MEDICAL SYSTEMS: COMPANY OVERVIEW
 
 
 
 
TABLE 532
MERIT MEDICAL SYSTEMS: PRODUCTS/SOLUTIONS/SERVICES OFFERED
 
 
 
 
TABLE 533
MERIT MEDICAL SYSTEMS: EXPANSIONS, JANUARY 2021– DECEMBER 2024
 
 
 
 
TABLE 534
JOHNSON & JOHNSON MEDTECH (ETHICON): COMPANY OVERVIEW
 
 
 
 
TABLE 535
JOHNSON & JOHNSON MEDTECH (ETHICON): PRODUCTS/SOLUTIONS/ SERVICES OFFERED
 
 
 
 
TABLE 536
TELEFLEX INCORPORATED: COMPANY OVERVIEW
 
 
 
 
TABLE 537
TELEFLEX INCORPORATED: PRODUCTS/SOLUTIONS/SERVICES OFFERED
 
 
 
 
TABLE 538
ANGIODYNAMICS: COMPANY OVERVIEW
 
 
 
 
TABLE 539
ANGIODYNAMICS: PRODUCTS/SOLUTIONS/SERVICES OFFERED
 
 
 
 
TABLE 540
ANGIODYNAMICS: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–DECEMBER 2024
 
 
 
 
TABLE 541
STRYKER: COMPANY OVERVIEW
 
 
 
 
TABLE 542
STRYKER: PRODUCTS/SOLUTIONS/SERVICES OFFERED
 
 
 
 
TABLE 543
IMBIOTECHNOLOGIES LTD.: COMPANY OVERVIEW
 
 
 
 
TABLE 544
IMBIOTECHNOLOGIES LTD.: PRODUCTS/SOLUTIONS/SERVICES OFFERED
 
 
 
 
TABLE 545
COOK: COMPANY OVERVIEW
 
 
 
 
TABLE 546
COOK: PRODUCTS/SOLUTIONS/SERVICES OFFERED
 
 
 
 
TABLE 547
ICECURE MEDICAL: COMPANY OVERVIEW
 
 
 
 
TABLE 548
ICECURE MEDICAL: PRODUCTS/SOLUTIONS/SERVICES OFFERED
 
 
 
 
TABLE 549
ICECURE MEDICAL LTD.: PRODUCT APPROVALS
 
 
 
 
TABLE 550
ICECURE MEDICAL LTD.: DEALS
 
 
 
 
TABLE 551
MEDWAVES, INC.: COMPANY OVERVIEW
 
 
 
 
TABLE 552
MEDWAVES INC.: PRODUCTS/SOLUTIONS/SERVICES OFFERED
 
 
 
 
TABLE 553
PROFOUND MEDICAL: COMPANY OVERVIEW
 
 
 
 
TABLE 554
PROFOUND MEDICAL: PRODUCTS/SOLUTIONS/SERVICES OFFERED
 
 
 
 
TABLE 555
RF MEDICAL CO., LTD.: COMPANY OVERVIEW
 
 
 
 
TABLE 556
RF MEDICAL CO., LTD.: PRODUCTS/SOLUTIONS/SERVICES OFFERED
 
 
 
 
TABLE 557
MINIMAX MEDICAL LIMITED: COMPANY OVERVIEW
 
 
 
 
TABLE 558
MINIMAX MEDICAL LIMITED: PRODUCTS/SOLUTIONS/SERVICES OFFERED
 
 
 
 
TABLE 559
ABK BIOMEDICAL INC.: COMPANY OVERVIEW
 
 
 
 
TABLE 560
ABK BIOMEDICAL INC.: PRODUCTS/SOLUTIONS/SERVICES OFFERED
 
 
 
 
TABLE 561
OLYMPUS CORPORATION: COMPANY OVERVIEW
 
 
 
 
TABLE 562
OLYMPUS CORPORATION: PRODUCTS/SOLUTIONS/SERVICES OFFERED
 
 
 
 
TABLE 563
SURGNOVA: COMPANY OVERVIEW
 
 
 
 
TABLE 564
SURGNOVA: PRODUCTS/SOLUTIONS/SERVICES OFFERED
 
 
 
 
TABLE 565
STARMED AMERICA: COMPANY OVERVIEW
 
 
 
 
TABLE 566
STARMED AMERICA: PRODUCTS/SOLUTIONS/SERVICES OFFERED
 
 
 
 
TABLE 567
SIRTEX SIR-SPHERES PTY LTD.: COMPANY OVERVIEW
 
 
 
 
TABLE 568
GUERBET: COMPANY OVERVIEW
 
 
 
 
TABLE 569
ACCURAY: COMPANY OVERVIEW
 
 
 
 
TABLE 570
EMBOLX, INC.: COMPANY OVERVIEW
 
 
 
 
TABLE 571
SONABLATE CORP.: COMPANY OVERVIEW
 
 
 
 
LIST OF FIGURES
 
 
 
 
 
FIGURE 1
INTERVENTIONAL ONCOLOGY MARKET SEGMENTATION
 
 
 
 
FIGURE 2
RESEARCH DESIGN
 
 
 
 
FIGURE 3
PRIMARY SOURCES
 
 
 
 
FIGURE 4
BREAKDOWN OF INTERVIEWS WITH EXPERTS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
 
 
 
 
FIGURE 5
BREAKDOWN OF INTERVIEWS WITH EXPERTS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION
 
 
 
 
FIGURE 6
BREAKDOWN OF INTERVIEWS WITH EXPERTS (DEMAND SIDE): BY END USER, DESIGNATION, AND REGION
 
 
 
 
FIGURE 7
SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
 
 
 
 
FIGURE 8
REVENUE SHARE ANALYSIS ILLUSTRATION: SIEMENS HEALTHINEERS AG (2023)
 
 
 
 
FIGURE 9
SUPPLY-SIDE MARKET SIZE ESTIMATION: INTERVENTIONAL ONCOLOGY MARKET (2023)
 
 
 
 
FIGURE 10
TOP-DOWN APPROACH
 
 
 
 
FIGURE 11
ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2024–2029)
 
 
 
 
FIGURE 12
CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
 
 
 
 
FIGURE 13
DATA TRIANGULATION METHODOLOGY
 
 
 
 
FIGURE 14
EMBOLIZATION DEVICES SEGMENT TO DOMINATE INTERVENTIONAL ONCOLOGY MARKET DURING FORECAST PERIOD (USD MILLION)
 
 
 
 
FIGURE 15
LIVER CANCER TYPE SEGMENT TO LEAD MARKET DURING FORECAST PERIOD (USD MILLION)
 
 
 
 
FIGURE 16
THERMAL TUMOR ABLATION SEGMENT TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD (USD MILLION)
 
 
 
 
FIGURE 17
HOSPITALS SEGMENT TO DOMINATE INTERVENTIONAL ONCOLOGY MARKET DURING FORECAST PERIOD (USD MILLION)
 
 
 
 
FIGURE 18
NORTH AMERICA ACCOUNTED FOR LARGEST SHARE OF INTERVENTIONAL ONCOLOGY MARKET IN 2023
 
 
 
 
FIGURE 19
GROWING DEMAND FOR INTERVENTIONAL ONCOLOGY TO DRIVE MARKET
 
 
 
 
FIGURE 20
EMBOLIZATION DEVICES ACCOUNTED FOR LARGEST SHARE OF INTERVENTIONAL ONCOLOGY MARKET IN 2023
 
 
 
 
FIGURE 21
CHINA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD
 
 
 
 
FIGURE 22
NORTH AMERICA TO DOMINATE MARKET DURING FORECAST PERIOD
 
 
 
 
FIGURE 23
EMERGING MARKETS TO REGISTER HIGHER GROWTH RATES DURING FORECAST PERIOD
 
 
 
 
FIGURE 24
DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN INTERVENTIONAL ONCOLOGY MARKET
 
 
 
 
FIGURE 25
VALUE CHAIN ANALYSIS: MAXIMUM VALUE ADDED DURING MANUFACTURING PHASE
 
 
 
 
FIGURE 26
INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF EMBOLIZATION DEVICES, ABLATION DEVICES, AND SUPPORT DEVICES
 
 
 
 
FIGURE 27
KEY BUYING CRITERIA FOR EMBOLIZATION DEVICES, ABLATION DEVICES, AND SUPPORT DEVICES
 
 
 
 
FIGURE 28
PREMARKET NOTIFICATION: 510(K) APPROVALS FOR MEDICAL DEVICES
 
 
 
 
FIGURE 29
CANADA: REGULATORY APPROVAL PROCESS FOR MEDICAL DEVICES
 
 
 
 
FIGURE 30
EUROPE: CE APPROVAL PROCESS FOR MEDICAL DEVICES
 
 
 
 
FIGURE 31
REVENUE SHIFT IN INTERVENTIONAL ONCOLOGY MARKET
 
 
 
 
FIGURE 32
PATENT PUBLICATION TRENDS, JANUARY 2014–DECEMBER 2024
 
 
 
 
FIGURE 33
TOP PATENT APPLICANTS AND OWNERS (COMPANIES/INSTITUTES) FOR INTERVENTIONAL ONCOLOGY, JANUARY 2014–DECEMBER 2024
 
 
 
 
FIGURE 34
TOP APPLICANT JURISDICTIONS FOR INTERVENTIONAL ONCOLOGY PATENTS, JANUARY 2014–DECEMBER 2024
 
 
 
 
FIGURE 35
AVERAGE SELLING PRICE OF INTERVENTIONAL ONCOLOGY DEVICES, BY KEY PLAYER, 2023
 
 
 
 
FIGURE 36
END USER EXPECTATIONS IN EMBOLIZATION DEVICES, ABLATION DEVICES, AND SUPPORT DEVICES
 
 
 
 
FIGURE 37
INTERVENTIONAL ONCOLOGY MARKET: ECOSYSTEM
 
 
 
 
FIGURE 38
INTERVENTIONAL ONCOLOGY MARKET: SUPPLY CHAIN ANALYSIS
 
 
 
 
FIGURE 39
ADJACENT MARKETS TO INTERVENTIONAL ONCOLOGY MARKET
 
 
 
 
FIGURE 40
INVESTMENT/VENTURE CAPITAL SCENARIO IN INTERVENTIONAL ONCOLOGY MARKET, 2020–2023
 
 
 
 
FIGURE 41
CHINA TO GROW AT HIGHEST CAGR IN INTERVENTIONAL ONCOLOGY MARKET DURING FORECAST PERIOD
 
 
 
 
FIGURE 42
NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET SNAPSHOT
 
 
 
 
FIGURE 43
EUROPE: INTERVENTIONAL ONCOLOGY MARKET SNAPSHOT
 
 
 
 
FIGURE 44
ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET SNAPSHOT
 
 
 
 
FIGURE 45
REVENUE SHARE ANALYSIS OF KEY PLAYERS IN INTERVENTIONAL ONCOLOGY MARKET,2019−2023
 
 
 
 
FIGURE 46
INTERVENTIONAL ONCOLOGY MARKET SHARE ANALYSIS, BY KEY PLAYER, 2023
 
 
 
 
FIGURE 47
INTERVENTIONAL ONCOLOGY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
 
 
 
 
FIGURE 48
INTERVENTIONAL ONCOLOGY MARKET: COMPANY FOOTPRINT
 
 
 
 
FIGURE 49
INTERVENTIONAL ONCOLOGY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
 
 
 
 
FIGURE 50
EV/EBITDA OF KEY VENDORS
 
 
 
 
FIGURE 51
YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
 
 
 
 
FIGURE 52
INTERVENTIONAL ONCOLOGY MARKET: COMPARATIVE BRAND ANALYSIS
 
 
 
 
FIGURE 53
SIEMENS HEALTHINEERS AG (VARIAN): COMPANY SNAPSHOT (2024)
 
 
 
 
FIGURE 54
BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT (2023)
 
 
 
 
FIGURE 55
MEDTRONIC: COMPANY SNAPSHOT (2024)
 
 
 
 
FIGURE 56
TERUMO CORPORATION: COMPANY SNAPSHOT (2024)
 
 
 
 
FIGURE 57
MERIT MEDICAL SYSTEMS: COMPANY SNAPSHOT (2023)
 
 
 
 
FIGURE 58
JOHNSON & JOHNSON MEDTECH (ETHICON): COMPANY SNAPSHOT (2023)
 
 
 
 
FIGURE 59
TELEFLEX INCORPORATED: COMPANY SNAPSHOT (2023)
 
 
 
 
FIGURE 60
ANGIODYNAMICS: COMPANY SNAPSHOT (2024)
 
 
 
 
FIGURE 61
STRYKER: COMPANY SNAPSHOT (2023)
 
 
 
 
FIGURE 62
ICECURE MEDICAL LTD.: COMPANY SNAPSHOT (2023)
 
 
 
 
FIGURE 63
OLYMPUS CORPORATION: COMPANY SNAPSHOT (2024)
 
 
 
 

Methodology

The study involved four major activities to estimate the current size of the Interventional Oncology market. Exhaustive secondary research was done to collect information on the market and its different subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Thereafter, market breakdown and data triangulation procedures were used to estimate the market size of the segments and subsegments.

Secondary Research

In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to to identify and collect information for the study of Interventional oncology market. It was also used to obtain important information about the top players, market classification, and segmentation according to industry trends to the bottom-most level, geographic markets, and key developments related to the market. A database of the key industry leaders was also prepared using secondary research.

Primary Research

Extensive primary research was conducted after obtaining information regarding the Interventional oncology market scenario through secondary research. Several primary interviews were conducted with market experts from both the demand and supply sides across major countries of North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Primary data was collected through questionnaires, emails, and telephonic interviews. The primary sources from the supply side included various industry experts, such as Chief X Officers (CXOs), Vice Presidents (VPs), Directors from business development, marketing, product development/innovation teams, and related key executives from manufacturers; distributors operating in the Interventional oncology market.; and key opinion leaders.

Primary interviews were conducted to gather insights such as market statistics, data on revenue collected from the products and services, market breakdowns, market size estimations, market forecasting, and data triangulation. Primary research also helped in understanding the various trends related to technology, application, vertical, and region. Stakeholders from the demand side customers/end users who are using infection control products were interviewed to understand the buyer’s perspective on the suppliers, products, and their current usage and the future outlook of their business, which will affect the overall market.

The following is a breakdown of the primary respondents:

Interventional Oncology Market

Note 1: C-level primaries include CEOs, COOs, CTOs, and VPs.

Note 2: Other primaries include sales managers, marketing managers, and product managers.

Note 3: Companies are classified into tiers based on their total revenue.

As of 2023: Tier 1=>USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, Tier 3=< USD 500 million.

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The research methodology used to estimate the size of the interventional oncology market includes the following details.

The market sizing of the market was undertaken from the global side.

Country-level Analysis: The size of the Interventional oncology market was obtained from the annual presentations of leading players and secondary data available in the public domain. The share of products in the overall Interventional oncology market was obtained from secondary data and validated by primary participants to arrive at the total Interventional Oncology market. Primary participants further validated the numbers.

Geographic market assessment (by region & country): The geographic assessment was done using the following approaches:

Approach 1: Geographic revenue contributions/splits of leading players in the market (wherever available) and respective growth trends

Approach 2: Geographic adoption trends for individual devices & consumables segments by end users and growth prospects for each of the segments (assumptions and indicative estimates validated from primary interviews)

At each point, the assumptions and approaches were validated through industry experts contacted during primary research. Considering the limitations of data available from secondary research, revenue estimates for individual companies (for the overall Interventional oncology market and geographic market assessment) were ascertained based on a detailed analysis of their respective product offerings, geographic reach/strength (direct or through distributors or suppliers), and the shares of the leading players in a particular region or country.

Global Interventional Oncology market Size: Bottom -Up Approach & Top – down approach

Interventional Oncology Market

Data Triangulation

The market was split into several segments and subsegments after arriving at the overall market size—using the market size estimation processes. Data triangulation and market breakdown procedures were employed to complete the overall market engineering process and arrive at the exact statistics of each market segment and sub-segment. The data was triangulated by studying various factors and trends from both the demand and supply sides in the Interventional Oncology market.

Market Definition

Interventional Oncology is a type of cancer treatment that includes minimally invasive treatment procedures and associated products involving tumor ablation and embolization techniques which are supported by image guidance and sometimes a contrast agent. Interventional Oncology is an alternative to chemotherapy, radiation oncology, and surgical oncology offering target specific treatment of cancer with least damage caused to the surrounding healthy cells. Interventional oncology is widely considered as a sub-specialty of interventional radiology.

Stakeholders

  • Minimally invasive medical devices, ablation, and embolization product manufacturing companies
  • Distributors, suppliers, and commercial service providers
  • Healthcare service providers
  • Clinical Research Organizations (CROs)
  • Ablation and embolization service providers
  • Minimally invasive medical devices, ablation, and embolization product distributors
  • Medical research laboratories
  • Market research and consulting firms
  • Academic medical centers and universities
  • Cancer research organizations

Report Objectives

  • To define, describe, segment, and forecast the global Interventional Oncology market by types and region.
  • To provide detailed information about the factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
  • To analyze micromarkets1 concerning individual growth trends, prospects, and contributions to the overall Interventional Oncology market.
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players.
  • To forecast the size of the Interventional Oncology market in five main regions along with their respective key countries, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
  • To profile key players in the global Interventional Oncology market and comprehensively analyze their core competencies2 and market shares.
  • To track and analyze competitive developments such as acquisitions, expansions, partnerships, agreements, and collaborations; and product launches and approvals.
  • To benchmark players within the Interventional Oncology market using the "Competitive Leadership Mapping" framework, which analyzes market players on various parameters within the broad categories of business and product strategy.

 

Key Questions Addressed by the Report

What is the expected addressable market value of the Interventional oncology market over 5 years?
The poultry pharmaceuticals market is projected to reach USD 4.24 billion by 2029 from USD 2.75 billion in 2024, at a CAGR of 9.0% during the forecast period.
What are the key drivers for the Interventional oncology market?
The overall driving forces for the interventional oncology market are the increasing prevalence of cancer globally, which has led to a higher need for effective treatment options. Preference of minimally invasive procedures like TACE, radioembolization, and ablation techniques is another significant factor because they provide a lesser duration to recover, less complications occur, and patient outcome is enhanced against traditional surgery.
Which country/region occupies the largest share of the Interventional oncology market, globally?
The interventional oncology market is dominated by North America due to the well-developed health care infrastructure in the region, widespread acceptance of advanced medical technologies, and rising cancer cases. The United States is the biggest market within this region due to the existence of a well-established network of cancer centers and hospitals with modern facilities for interventional radiology.
What are the strategies adopted by the top market players to penetrate emerging regions?
The major players in the market use partnerships, expansions, distribution agreements, product launches, and product approvals as important growth tactics.
What are the main players present in this market?
The main vendors in the market are include Siemens Healthineers AG (Varian) (US), Medtronic (Ireland), Boston Scientific Corporation (US), Terumo Corporation (Japan), Merit Medical Systems (US), Johnson & Johnson MedTech (Ethicon) (US), Stryker (US), Teleflex Incorporated (US), AngioDynamics (US).

TABLE OF CONTENTS

METHODOLOGY

Adjacent Markets

Request Bundle Reports

Personalize This Research

  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
Request A Free Customisation

Let Us Help You

  • What are the Known and Unknown Adjacencies Impacting the Interventional Oncology Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
Customized Workshop Request
Forbes

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Get 10% Free Customisation

Growth opportunities and latent adjacency in Interventional Oncology Market

DMCA.com Protection Status